Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome
Recruiting
N/A
Interventional Study
22Q11 Deletion Syndrome
tACS
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 14 – 25
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Stephan Eliez · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this project is to explore the effects of transcranial alternating current stimulation (tACS) in children, adolescents and young adults with a 22q11.2 microdeletion. The main aim of the present research project is to investigate the effects of repeated, individually tuned high-density (HD) tACS on cognition (i.e., WM performance) and related neuroimaging markers in carriers of the 2…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Confirmed genetic diagnosis of 22q11DS
* Age between 14 and 25 years old
* Willingness to participate
* Informed Consent signed by the subject and/or the caregiver(s)
Exclusion Criteria:
* Epilepsy
* Deep brain stimulation electrodes
* Traumatic brain injury
* Facial metal i…
Contacts
No contact information available.